Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, I.-A.
Right arrow Articles by Bernhard, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, I.-A.
Right arrow Articles by Bernhard, E. J.
[Cancer Research 65, 7902-7910, September 1, 2005]
© 2005 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Selective Inhibition of Ras, Phosphoinositide 3 Kinase, and Akt Isoforms Increases the Radiosensitivity of Human Carcinoma Cell Lines

In-Ah Kim1, Sun-Sik Bae2, Annemarie Fernandes1, JunMin Wu1, Ruth J. Muschel3, W. Gillies McKenna1, Morris J. Birnbaum2 and Eric J. Bernhard1

1 Department of Radiation Oncology and 2 Howard Hughes Medical Institute, University of Pennsylvania; and 3 Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Requests for reprints: Eric J. Bernhard, Department of Radiation Oncology, University of Pennsylvania, 185 John Morgan Building, Philadelphia, PA 19104-6072. E-mail: bernhard{at}mail.med.upenn.edu.

Ras activation promotes the survival of tumor cells after DNA damage. To reverse this survival advantage, Ras signaling has been targeted for inhibition. Other contributors to Ras-mediated DNA damage survival have been identified using pharmacologic inhibition of signaling, but this approach is limited by the specificity of the inhibitors used and their toxicity. To better define components of Ras signaling that could be inhibited in a clinical setting, RNA interference was used to selectively block expression of specific isoforms of Ras, phosphoinositide 3 (PI3) kinase, and Akt. Inhibition of oncogenic Ras expression decreased both phospho-Akt and phospho-p42/44 mitogen-activated protein (MAP) kinase levels and reduced clonogenic survival. Because pharmacologic inhibition of PI3 kinases and Akt radiosensitized cell lines with active Ras signaling, whereas inhibition of the MAP/extracellular signal–regulated kinase (ERK) kinase/ERK pathway did not, we examined the contribution of PI3 kinases and Akts to radiation survival. Selective inhibition the PI3 kinase P110{alpha} + p85ß isoforms reduced Akt phosphorylation and radiation survival. Similarly, inhibition of Akt-1 reduced tumor cell radiation survival. Inhibition of Akt-2 or Akt-3 had less effect. Retroviral transduction and overexpression of mouse Akt-1 was shown to rescue cells from inhibition of endogenous human Akt-1 expression. This study shows that Ras signaling to the PI3 kinase–Akt pathway is an important contributor to survival, whether Ras activation results from mutation of ras or overexpression of epidermal growth factor receptor. This study further shows that selective inhibition of the PI3 kinase P110{alpha} + p85ß isoforms or Akt-1 could be a viable approach to sensitizing many tumor cells to cytotoxic therapies.




This article has been cited by other articles:


Home page
Cancer Res.Home page
R. Prevo, E. Deutsch, O. Sampson, J. Diplexcito, K. Cengel, J. Harper, P. O'Neill, W. G. McKenna, S. Patel, and E. J. Bernhard
Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity
Cancer Res., July 15, 2008; 68(14): 5915 - 5923.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. C. Park, H. J. Zhang, E. S. Yao, C. J. Park, and M. J. Bissell
{beta}1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts
Cancer Res., June 1, 2008; 68(11): 4398 - 4405.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. S. Chen, L. J. Zhou, M. Entin-Meer, X. Yang, M. Donker, Z. A. Knight, W. Weiss, K. M. Shokat, D. Haas-Kogan, and D. Stokoe
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma
Mol. Cancer Ther., April 1, 2008; 7(4): 841 - 850.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
M. Toulany, M. Baumann, and H. P. Rodemann
Stimulated PI3K-AKT Signaling Mediated through Ligand or Radiation-Induced EGFR Depends Indirectly, but not Directly, on Constitutive K-Ras Activity
Mol. Cancer Res., August 1, 2007; 5(8): 863 - 872.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. D. Kao, Z. Jiang, A. M. Fernandes, A. K. Gupta, and A. Maity
Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation
J. Biol. Chem., July 20, 2007; 282(29): 21206 - 21212.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Jiang, N. Pore, G. J. Cerniglia, R. Mick, M.-M. Georgescu, E. J. Bernhard, S. M. Hahn, A. K. Gupta, and A. Maity
Phosphatase and Tensin Homologue Deficiency in Glioblastoma Confers Resistance to Radiation and Temozolomide that Is Reversed by the Protease Inhibitor Nelfinavir
Cancer Res., May 1, 2007; 67(9): 4467 - 4473.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Pervin, R. Singh, E. Hernandez, G. Wu, and G. Chaudhuri
Nitric Oxide in Physiologic Concentrations Targets the Translational Machinery to Increase the Proliferation of Human Breast Cancer Cells: Involvement of Mammalian Target of Rapamycin/eIF4E Pathway
Cancer Res., January 1, 2007; 67(1): 289 - 299.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Pore, A. K. Gupta, G. J. Cerniglia, Z. Jiang, E. J. Bernhard, S. M. Evans, C. J. Koch, S. M. Hahn, and A. Maity
Nelfinavir Down-regulates Hypoxia-Inducible Factor 1{alpha} and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy.
Cancer Res., September 15, 2006; 66(18): 9252 - 9259.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. Rasoulpour, K. DiPalma, B. Kolvek, and M. Hixon
Akt1 Suppresses Radiation-Induced Germ Cell Apoptosis in Vivo
Endocrinology, September 1, 2006; 147(9): 4213 - 4221.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Toulany, U. Kasten-Pisula, I. Brammer, S. Wang, J. Chen, K. Dittmann, M. Baumann, E. Dikomey, and H. P. Rodemann
Blockage of Epidermal Growth Factor Receptor-Phosphatidylinositol 3-Kinase-AKT Signaling Increases Radiosensitivity of K-RAS Mutated Human Tumor Cells In vitro by Affecting DNA Repair.
Clin. Cancer Res., July 1, 2006; 12(13): 4119 - 4126.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. de la Pena, W. E. Burgan, D. J. Carter, M. G. Hollingshead, M. Satyamitra, K. Camphausen, and P. J. Tofilon
Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells.
Mol. Cancer Ther., June 1, 2006; 5(6): 1504 - 1510.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. R. Vink, S. Lagerwerf, E. Mesman, J. H.M. Schellens, A. C. Begg, W. J. van Blitterswijk, and M. Verheij
Radiosensitization of Squamous Cell Carcinoma by the Alkylphospholipid Perifosine in Cell Culture and Xenografts
Clin. Cancer Res., March 1, 2006; 12(5): 1615 - 1622.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.